Treatment of patient-derived CML cells grown in culture with IFN-α also showed decreased cell growth via upregulation of p38, and this effect was also reversed with a p38 inhibitor. This evidence concerns the gene IFNA1 and chronic myelogenous leukemia, BCR-ABL1 positive.